The signature-enriched pathways in GEM and PAL treatment groups were “bladder cancer and HIF-1α signaling”, and “cell cycle, p53 signaling, and ECM-receptor interaction”, respectively. The gene discussed is HIF1A; the disease is urinary bladder carcinoma.